Last 12 months
Inside the activity.
1 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062065 · ownership.xml · derivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062065 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,351 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
GrantCommon Stock, $.01 Par Value | 287,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062068 · ownership.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,132,967 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed Mar 29, 2025 00:20 UTC Amendment |
Prentiss Christopher BChief Financial Officer
|
GrantCommon Stock, $.01 Par Value | 103,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-047091 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,600 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Correction of vesting: 4-year vesting schedule with 1/3rd of shares vesting on the second anniversary of the vesting determination date of April 22, 2024 and on each anniversary thereafter until fully vested. Read SEC document |
| May 13, 2024 Filed May 15, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
SaleCommon Stock, $.01 Par Value | 3,618 | $4.31 | $15,593.58 |
DisclosureSEC source: 0000950170-24-059963 · ownership.xml · nonDerivative · entry 2 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 845,967 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 18,2023. Read SEC document |
| May 13, 2024 Filed May 15, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
SaleCommon Stock, $.01 Par Value | 3,047 | $4.31 | $13,132.57 |
DisclosureSEC source: 0000950170-24-059962 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 783,446 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
Tax withholdingCommon Stock, $.01 Par Value | 8,028 | $4.32 | $34,680.96 |
DisclosureSEC source: 0000950170-24-059963 · ownership.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 849,585 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 34,830 | $4.32 | $150,465.60 |
DisclosureSEC source: 0000950170-24-059961 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,149,260 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 12,342 | $4.32 | $53,317.44 |
DisclosureSEC source: 0000950170-24-059962 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 786,493 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 8,028 | $4.32 | $34,680.96 |
DisclosureSEC source: 0000950170-24-059960 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,016,704 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| March 27, 2024 Filed Mar 30, 2024 01:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 17,084 | $4.63 | $79,098.92 |
DisclosureSEC source: 0000950170-24-038816 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,351 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $0.01 Par Value | 15,290 | $3.27 | $49,998.30 |
DisclosureSEC source: 0001209191-24-002744 · doc4.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,732 F3 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
BLANK BURKHARDEVP Chief Medical Officer
|
GrantCommon Stock, $0.01 Par Value | 152,905 | $3.27 | $499,999.35 |
DisclosureSEC source: 0001209191-24-002743 · doc4.xml · nonDerivative · entry 2 BLANK BURKHARD · CIK 0001073409 · EVP Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,905 F2 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
Kay SabrinaDirector
|
GrantCommon Stock, $0.01 Par Value | 107,033 | $3.27 | $349,997.91 |
DisclosureSEC source: 0001209191-24-002742 · doc4.xml · nonDerivative · entry 1 Kay Sabrina · CIK 0001835895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,600 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantCommon Stock, $0.01 Par Value | 15,290 | $3.27 | $49,998.30 |
DisclosureSEC source: 0001209191-24-002740 · doc4.xml · nonDerivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,435 F2 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
Consiglio Ronald JDirector
|
GrantCommon Stock, $0.01 Par Value | 25,000 | $3.27 | $81,750.00 |
DisclosureSEC source: 0001209191-24-002739 · doc4.xml · nonDerivative · entry 1 CONSIGLIO RONALD J · CIK 0001232088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,997 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
HOOPER ANTHONY CDirector
|
GrantCommon Stock, $0.01 Par Value | 40,000 | $3.27 | $130,800.00 |
DisclosureSEC source: 0001209191-24-002741 · doc4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,153 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $0.01 Par Value | 30,581 | $3.27 | $99,999.87 |
DisclosureSEC source: 0001209191-24-002738 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,184,090 F3 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $0.01 Par Value | 1,006 | $3.09 | $3,108.54 |
DisclosureSEC source: 0001209191-24-002744 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,009,442 F2 · kind: Includes 1006 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC |
BLANK BURKHARDEVP Chief Medical Officer
|
GrantCommon Stock, $0.01 Par Value | 5,000 | $3.09 | $15,450.00 |
DisclosureSEC source: 0001209191-24-002743 · doc4.xml · nonDerivative · entry 1 BLANK BURKHARD · CIK 0001073409 · EVP Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 F1 · kind: Includes 5000 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantCommon Stock, $0.01 Par Value | 711 | $3.09 | $2,196.99 |
DisclosureSEC source: 0001209191-24-002740 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,145 F1 · kind: Includes 711 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $0.01 Par Value | 209 | $3.09 | $645.81 |
DisclosureSEC source: 0001209191-24-002738 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,153,509 F2 · kind: Includes 209 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| December 15, 2023 Filed Dec 16, 2023 02:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 90,482 | $4.00 | $361,928.00 |
DisclosureSEC source: 0001209191-23-058899 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,148,665 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established September 1, 2023. All transactions contemplated by such plan have now been completed. Read SEC document |
| December 14, 2023 Filed Dec 16, 2023 02:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 100,000 | $4.00 | $400,000.00 |
DisclosureSEC source: 0001209191-23-058899 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239,147 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established September 1, 2023. Read SEC document |
| December 14, 2023 Filed Dec 16, 2023 02:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.00 | $40,000.00 |
DisclosureSEC source: 0001209191-23-058899 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,339,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. All transactions contemplated by such plan have now been completed. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.25 | $42,500.00 |
DisclosureSEC source: 0001209191-23-054255 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,349,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 01:00 UTC |
Singh Sanjay REVP Technical Operations
|
Tax withholdingCommon Stock, $.01 Par Value | 17,071 | $4.29 | $73,234.59 |
DisclosureSEC source: 0001209191-23-054254 · doc4.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,179 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.61 | $46,100.00 |
DisclosureSEC source: 0001209191-23-051262 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 01:00 UTC Amendment |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.08 | $40,800.00 |
DisclosureSEC source: 0001209191-23-051766 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. F2 · price: Correction of price. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
OtherCommon Stock, $.01 Par Value | 66,892 | $4.91 | $328,439.72 |
DisclosureSEC source: 0001209191-23-048259 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,369,147 F2 · kind: Reporting person transferred 66,892 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree on September 5, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.61 | $46,100.00 |
DisclosureSEC source: 0001209191-23-048259 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,436,039 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
SaleCommon Stock, $.01 Par Value | 8,100 | $4.78 | $38,738.25 |
DisclosureSEC source: 0001209191-23-047550 · doc4.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 798,835 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established November 17, 2022. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 20,328 | $4.72 | $95,948.16 |
DisclosureSEC source: 0001209191-23-047552 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,134 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 50,696 | $4.72 | $239,285.12 |
DisclosureSEC source: 0001209191-23-047553 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,446,039 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 20,328 | $4.72 | $95,948.16 |
DisclosureSEC source: 0001209191-23-047551 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,004,424 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 20,328 | $4.72 | $95,948.16 |
DisclosureSEC source: 0001209191-23-047550 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 806,935 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 07, 2023 Filed Nov 20, 2024 02:30 UTC |
Binder Steven B.Director
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 45,025 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0000950170-24-128986 · ownership.xml · derivative · entry 3 Binder Steven B. · CIK 0001712601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,025 Underlying: Common Stock, $0.01 Par Value · 45,025 shares Expires 2027-08-24 F3 · kind: On August 24, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On August 7, 2023, one of the defined performance milestones was met, resulting in the vesting of the option. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.57 | $45,686.00 |
DisclosureSEC source: 0001209191-23-044093 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,496,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| July 05, 2023 Filed Jul 8, 2023 01:00 UTC Amendment |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 5,586 | $4.01 | $22,407.12 |
DisclosureSEC source: 0001209191-23-041868 · doc4a.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,506,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 10:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.07 | $40,701.00 |
DisclosureSEC source: 0001209191-23-040737 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,506,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| July 03, 2023 Filed Jul 8, 2023 01:00 UTC Amendment |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 4,414 | $4.07 | $17,965.42 |
DisclosureSEC source: 0001209191-23-041868 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,512,321 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| June 30, 2023 Filed Feb 5, 2024 11:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $0.01 Par Value | 4,012 | $3.46 | $13,881.52 |
DisclosureSEC source: 0001209191-24-002744 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,436 F1 · kind: Includes 4012 shares of common stock purchased under the Company's Employee Stock Purchase Plan on June 30, 2023 in an exempt transaction. Read SEC document |
| June 30, 2023 Filed Feb 5, 2024 11:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $0.01 Par Value | 4,635 | $3.46 | $16,037.10 |
DisclosureSEC source: 0001209191-24-002738 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,153,300 F1 · kind: Includes 4635 shares of common stock purchased under the Company's Employee Stock Purchase Plan on June 30, 2023 in an exempt transaction. Read SEC document |
| June 01, 2023 Filed Jun 3, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.53 | $45,302.00 |
DisclosureSEC source: 0001209191-23-034100 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,516,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| May 26, 2023 Filed May 27, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 75,000 | $4.50 | $337,335.00 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,526,735 F3 · kind: Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:01 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantPerformance Restricted Stock Unit · Derivative | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032728 · doc4.xml · derivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock, $.01 Par Value · 113,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:01 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantCommon Stock, $.01 Par Value | 92,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032728 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,263 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:01 UTC |
MUNDKUR CHRISTINEDirector
|
GrantRestricted Stock Unit · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032724 · doc4.xml · derivative · entry 1 MUNDKUR CHRISTINE · CIK 0001237264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Common Stock · 35,545 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032730 · doc4.xml · derivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock, $.01 Par Value · 28,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantCommon Stock, $.01 Par Value | 23,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032730 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,434 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.